• Medical Imaging Medical Imaging
  • Ophtalmology Ophtalmology
  • Operating Room Operating Room
  • Anesthesia Anesthesia
  • Laboratory Laboratory
  • Dental Equipment Dental Equipment
  • Gastroenterology Gastroenterology
  • Obstetrics and Gynecology Obstetrics and Gynecology
  • Cardiology Cardiology
  • Emergency Medicine Emergency Medicine
  • Comfort and Well-being Comfort and Well-being
  • Dermatology Dermatology
  • Healthcare Furniture Healthcare Furniture
  • Urology and Nephrology Urology and Nephrology
  • ENT ENT
  • Orthopaedics Orthopaedics
  • Physical Therapy and Rehabilitation Physical Therapy and Rehabilitation
  • Sterilization Sterilization
  • Intensive Care Intensive Care
  • Surgical Instruments Surgical Instruments

Bilirubinometer Dräger JM-105

Brand: Dräger

Be notified by email when the product is available
Subscribe to our partner program and become a Remma seller.


The Dräger JM-105 bilirubinometer provides precise and affordable screening for neonatal jaundice. Its user-friendly design allows detection from the 24th week of gestation, reducing readmission rates and hospital stay duration. The quick and stress-free measurement of transcutaneous bilirubin (TcB) ensures informed decision-making. The integrated signaling function simplifies monitoring of high-risk patients. Connected to the Hospital Information System, it ensures reliable data transfer. Eliminating the need for single-use tips, the JM-105 offers a cost-effective solution, combining efficiency and gentleness for newborns.

Description

Dräger JM-105 Bilirubinometer: Effective and Economical Screening for Neonatal Jaundice

The Dräger JM-105 bilirubinometer stands out as a comprehensive solution, combining efficiency and affordability for neonatal jaundice screening. This state-of-the-art technology provides reliable and cost-effective monitoring throughout its lifespan, ensuring optimal jaundice management in newborns, with high-quality care and savings in both time and money.

With its ability to precisely detect at-risk newborns from the 24th week of gestation, the JM-105 contributes to reducing readmission rates and the duration of hospital stays. Rapid results obtained in seconds enhance patient safety, expedite decision-making processes, and facilitate the tracking of patients requiring special attention through its integrated signaling function. This proactive approach ensures compliance with jaundice treatment protocols, offering individualized and targeted management.

User experience is at the core of the JM-105's design, providing transcutaneous bilirubin measurement (TcB) that avoids unnecessary stress for both newborns and their parents. The detection procedure is simplified with an easy-to-clean reusable probe, eliminating the need for single-use tips. This respectful and gentle approach makes it easier for healthcare professionals while providing a soothing environment for infants.

The JM-105's connectivity with the Hospital Information System ensures a reliable and seamless transfer of electronic data, ensuring efficient management of clinical information. By reducing the need for blood draws, the JM-105 optimizes the jaundice detection process, eliminating additional costs and time associated with laboratory analyses. Reliable measurements and a reduction in screening steps free up valuable time for direct care of newborns, reinforcing operational efficiency.

Advanced features such as data transfer and barcode scanning contribute to optimizing the screening program, minimizing the risk of human errors. The JM-105, equipped with a reusable probe, goes further by eliminating the need for single-use tips, generating significant long-term savings. This feature is particularly advantageous given the high volume of screening tests performed in neonatology.

The Dräger JM-105 bilirubinometer represents a comprehensive and cost-effective solution for neonatal jaundice management. Its approach, combining gentleness, efficiency, and connectivity, makes it an essential tool for healthcare professionals seeking to provide superior quality care while optimizing screening processes.

Features

    • Early detection of neonatal jaundice from the 24th week of gestation.
    • Reduction in readmission rates and length of hospital stay.
    • Quick results within seconds for informed decision-making.
    • Integrated signaling function for tracking at-risk patients.
    • User-friendly operation, minimizing stress for newborns and parents.
    • Measurement of transcutaneous bilirubin (TcB) without blood sampling.
    • Easy-to-clean reusable probe, eliminating the need for single-use tips.
    • Connectivity to the Hospital Information System for reliable data transfer.
    • Streamlining the screening process, reducing laboratory analysis costs.
    • Optimization of the screening program with data transfer and barcode scanning functions.
    • Significant long-term savings through the elimination of single-use tips.
    • Combination of gentleness for the newborn and efficiency for healthcare personnel.

Technical Details

DEVICE CLASSIFICATION

    • Protection Class according to IEC 60601-1 (Bilirubinometer): Electric medical equipment with internal power supply, type BF, continuous operation, not AP
    • Protection Class according to IEC 60601-1 (AC Adapter): Class I electric medical equipment with external drive, type BF, continuous operation, not AP
    • Liquid and Particle Ingress (IEC 60601-1): IPX0
    • Classification in accordance with European Directive 93/42/EEC Annex IX:
    • IIa
    • UMDNS/GMDN Code: 16-166/35475

ELECTRICAL FEATURES

    • Battery: Internal NiMH
    • Number of measurements (full charge): 250
    • Light source: Xenon flash lamp
    • Light source lifespan: 150,000 measurements
    • Sensors: Silicon photodiodes

PHYSICAL FEATURES

    • Width: 56 mm
    • Depth: 45 mm
    • Height: 168 mm
    • Weight: 203 g ± 10%

PERFORMANCE FEATURES

    • Measurement Range: 0.0 mg/dL to 20.0 mg/dL (0 µmol/L to 340 µmol/L)
    • Accuracy:
± 1.5 mg/dL or ± 25.5 µmol/L (> 35 weeks gestation)

± 1.6 mg/dL or ± 27.4 µmol/L (> 24 weeks gestation)

    • Accuracy after phototherapy:
± 2.3 mg/dL or ± 39.00 µmol/L (> 24 weeks gestation)

± 2.2 mg/dL or ± 38.00 µmol/L (> 35 weeks gestation)

DATA TRANSMISSION

    • USB Port: HL-7 or CSV

SUPPORTED BARCODE FORMATS

    • Code 39
    • EAN/JAN
    • Code 128
    • ANSI/HIBC

Caution: For more information, please refer to the PDF file.

Compatible Accessories

    • Reusable Probe: A reusable sampling probe, easy to clean, for precise and hygienic measurements.
    • Power Adapter: Maintains the power supply of the bilirubinometer for continuous operation.
    • Connection Cable: Ensures connectivity with the Hospital Information System for reliable transfer of electronic data.
    • Optional Disposable Tips: Disposable tips available as needed to meet specific hygiene requirements.
    • Optional Data Management Software: Software enabling centralized management of screening data.

Servicing and Logistics

Remma and its partners provide you with serviced and configured equipment tailored to your needs. Receive your product at your facility with standard or express delivery, and an installation option, all through a single point of contact.

Warranty

Our 12/24-month warranty ensures the safety and reliability of your medical equipment throughout its lifespan.

Flexible Financing

Settle your medical equipment in up to 36 installments with our financing service or pay after delivery with Remma Facility.